✦ LIBER ✦

A phase I study of chronic daily dosing of oral etoposide in combination with cisplatin for patients with advanced cancer

✍ Scribed by Masahiro Fukuoka; Noriyuki Masuda; Shunichi Negoro; Minoru Takada; Shinzoh Kudoh; Yoko Kusunoki; Kaoru Matsui; Nobuhide Takifuji; Akira Tachikawa; Masaaki Kawahara; Masunari Yamamoto; Kaoru Kubota; Nagahisa Kodama; Mitsumasa Ogawara; Kiyoyuki Furuse

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 440 KB
Volume: 68
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19910715)68:2<284::aid-cncr2820680212>3.0.co;2-k

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of a modified combination

Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric cancer

✍ Içli, Fikri; Karaoguz, Handan; Akbulut, Hakan; Dinçol, Dilek; Demirkazik, Ahmet; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB 👁 1 views

## Background: Based on the promising results of eap (etoposide, doxorubicin, and cisplatin) combination, a phase ii study of modified eap combination was performed in patients with advanced gastric cancer to evaluate the response, toxicity, and survival. ## Method: Fifty-two consecutive patients

A phase II study of gemcitabine plus ora

A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma

✍ Tony S. K. Mok; Benny Zee; Anthony T. C. Chan; Winnie Yeo; Wei Tse Yang; Anthony 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

A Phase I and pharmacokinetic study of h

A Phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma

✍ Edward F. McClay; Mary-Eileen T. McClay; Jeffery A. Jones; Paul J. Winski; Rando 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

by 40 mg to the MTD in groups of 3 patients. DDP (80 mg/m 2 ) was begun on Day ogy/Oncology, Hollings Cancer Center, Medical 2 and repeated weekly for a total of 3 weeks. During Week 4, the patients were University of South Carolina, Charleston, South not treated with DDP but instead evaluated for r

A phase II trial of weekly high dose con

A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer

✍ Enrique Aranda; Andrés Cervantes; Javier Dorta; Esperanza Blanco; Carlos Fernánd 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 1 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer

A phase I, II study of high-dose 5-fluor

A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies

✍ Bach Ardalan; Kasi S. Sridhar; Pasquale Benedetto; Stephen Richman; Stuart Waldm 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 454 KB 👁 1 views

Ex vivo ras peptide vaccination in patie

Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study

✍ Marianne K. Gjertsen; Arne Bakka; Jarle Breivik; Ingvil Saeterdal; Tobias Gedde- 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 French ⚖ 434 KB 👁 2 views

In a pilot phase 1/11 study we have tested synthetic ras peptides used as a cancer vaccine in 5 patients with advanced pancreatic carcinoma. The treatment principle used was based on loading professional antigen-presenting cells (APCs) from peripheral blood with a synthetic ras peptide corresponding